Showing 4571-4580 of 6037 results for "".
- 2023 Medscape Report: Physician Salaries Rise as Gender Gap Narrowshttps://practicaldermatology.com/news/2023-medscape-report-physician-salaries-rise-as-gender-gap-narrows/2461663/Doctor salaries continue to rise as the gender gap narrows, according to the 2023 Medscape Physician Compensation Report. The largest difference for women was seen in primary care, but the disparity also narrowed within specialties, from a 36% difference i
- Adding New Personalized Vaccine to Immunotherapy Slashes Risk for Melanoma Recurrencehttps://practicaldermatology.com/news/adding-new-personalized-vaccine-to-immunotherapy-slashes-risk-for-melanoma-recurrence/2461662/Adding an experimental mRNA vaccine to immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared with immunotherapy alone, a new clinical trial shows. The phase 2b trial results were presented at the annual meeting of the American A
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA
- The American Acne and Rosacea Society Offers #RosaceaRescues During Rosacea Awareness Monthhttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-offers-rosacearescues-during-rosacea-awareness-month/2461647/In recognition of National Rosacea Awareness Month in April, experts from the American Acne and Rosacea Society (AARS) are working to educate the public about the disease, its impact, and its treatment. Throughout the month, they are sharing #RosaceaRescues—science-backed, medically-based s
- Building a Better Sunscreen: Is Rosmarinic Acid the Key?https://practicaldermatology.com/news/building-a-better-sunscreen-is-rosmarinic-acid-the-key/2461646/Rosmarinic acid may enhance sunscreen efficacy without increasing concentration of conventional UV filters, a new study in Cosmetics suggests. When 0.1% Rosmarinic acid an active antioxidant was added
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was
- Phase 3 Studies Show Lebrikizumab Effective in Patients With Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/phase-3-studies-show-lebrikizumab-effective-in-patients-with-moderate-to-severe-atopic-dermatitis/2461630/After 16 weeks of treatment, lebrikizumab (Almirall) was effective in adolescents and adults with moderate-to-severe atopic dermatitis, according to two Phase 3 studies. The research was published in the New England Journal of